多发性骨髓瘤常用表面抗原的生物活性和预后意义
Biological Activity and Prognostic Significance of Common Surface Antigens in Multiple Myeloma
DOI: 10.12677/ACM.2023.133552, PDF,   
作者: 刘红利, 娄世锋*：重庆医科大学附属第二医院血液内科，重庆
关键词: 表面抗原；多发性骨髓瘤；流式细胞术；预后；Surface Antigen； Multiple Myeloma； Flow Cytometry； Prognosis
摘要: 多发性骨髓瘤(multiple myeloma, MM)是一种复杂的异质性疾病，积聚在骨髓中的异常克隆性浆细胞(plasma cells, PC)不受控制和破坏性的生长，最终导致多种组织器官损害。MM的进展依赖于其与骨髓微环境和免疫系统的相互作用，并由关键的表面抗原介导。一些抗原促进与骨髓基质和基质细胞的黏附，而另一些则参与细胞间的相互作用，导致B细胞向PC的分化。这些相互作用也参与了正常PC向MM PC的恶变以及疾病的进展。我们综述了在MM的流式细胞术中常用的一些表面抗原，用于鉴定PC、区别正常和恶性PC以及预测预后。这些标记物包括：CD38、CD138、CD45、CD27、CD19、CD28、CD56、CD81、CD117和CD24。综述了每种抗原的生物活性，以及它在正常和恶性PC中的表达情况、预后意义和治疗潜力。了解这些特定表面抗原的作用，可以对MM患者进行更个性化的预后监测和治疗。
Abstract: Multiple myeloma is a complex heterogeneous disease with uncontrolled and destructive growth of abnormal clonal plasma cells accumulated in the bone marrow, resulting in a variety of tissue and organ damage. The progression of multiple myeloma depends on its interaction with the bone mar-row microenvironment and immune system, and is mediated by key surface antigens. Some anti-gens promote adhesion to bone marrow stroma and stromal cells, while others participate in cell-to-cell interaction, leading to the differentiation of B cells into plasma cells. These interactions are also involved in the malignant transformation of normal plasma cells to myeloma plasma cells and the progression of the disease. We review some surface antigens commonly used in flow cytom-etry of multiple myeloma to identify plasma cells, distinguish normal and malignant plasma cells, and predict prognosis. These markers include: CD38, CD138, CD45, CD27, CD19, CD28, CD56, CD81, CD117 and CD24. The biological activity of each antigen, its expression in normal and malignant plasma cells, prognostic significance and therapeutic potential were reviewed. Understanding the role of these specific surface antigens can provide more personalized prognostic monitoring and treatment for patients with multiple myeloma.
文章引用：刘红利, 娄世锋. 多发性骨髓瘤常用表面抗原的生物活性和预后意义[J]. 临床医学进展, 2023, 13(3): 3852-3859. https://doi.org/10.12677/ACM.2023.133552

参考文献

[1] Palumbo, A. and Anderson, K. (2011) Multiple Myeloma. The New England Journal of Medicine, 364, 1046-1060. [Google Scholar] [CrossRef] 
[2] Rajkumar, S.V., Dimopoulos, M.A., Palumbo, A., et al. (2014) In-ternational Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. The Lancet Oncology, 15, e538-e548. [Google Scholar] [CrossRef] 
[3] Varettoni, M., Corso, A., Pica, G., et al. (2010) Incidence, Presenting Features and Outcome of Extramedullary Disease in Multiple Myeloma: A Longitudinal Study on 1003 Con-secutive Patients. Annals of Oncology, 21, 325-330. [Google Scholar] [CrossRef] [PubMed]
[4] Short, K.D., Rajkumar, S.V., Larson, D., et al. (2011) Incidence of Extramedullary Disease in Patients with Multiple Myeloma in the Era of Novel Therapy, and the Activity of Pomalido-mide on Extramedullary Myeloma. Leukemia, 25, 906-908. [Google Scholar] [CrossRef] [PubMed]
[5] Giannakoulas, N., Ntanasis-Stathopoulos, I. and Terpos, E. (2021) The Role of Marrow Microenvironment in the Growth and Devel-opment of Malignant Plasma Cells in Multiple Myeloma. International Journal of Molecular Sciences, 22, 4462. [Google Scholar] [CrossRef] [PubMed]
[6] Francesco, D.M., Christina, Y., Annamaria, C., et al. (2021) Mapping the High-Risk Multiple Myeloma Cell Surface Proteome Identifies T-Cell Inhibitory Receptors for Immune Targeting. Blood, 138, 265. [Google Scholar] [CrossRef] 
[7] Alaterre, E., Raimbault, S., Goldschmidt, H., et al. (2017) CD24, CD27, CD36 and CD302 Gene Expression for Outcome Prediction in Patients with Multiple Myeloma. Oncotarget, 8, 98931-98944. [Google Scholar] [CrossRef] [PubMed]
[8] Flores-Montero, J., Sanoja-Flores, L., Paiva, B., et al. (2017) Next Generation Flow for Highly Sensitive and Standardized Detection of Minimal Residual Disease in Multiple Myeloma. Leukemia, 31, 2094-2103. [Google Scholar] [CrossRef] [PubMed]
[9] Deaglio, S., Mehta, K. and Malavasi, F. (2001) Human CD38: A (r)evolutionary Story of Enzymes and Receptors. Leukemia Research, 25, 1-12. [Google Scholar] [CrossRef] 
[10] Costa, F., Dalla Palma, B. and Giuliani, N. (2019) CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeu-tic Agents. Cells, 8, 1632. [Google Scholar] [CrossRef] [PubMed]
[11] Saltarella, I., Desantis, V., Melaccio, A., et al. (2020) Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. Cells, 9, 167. [Google Scholar] [CrossRef] [PubMed]
[12] Van de Donk, N.W., Janmaat, M.L., Mutis, T., et al. (2016) Monoclonal Antibodies Targeting CD38 in Hematological Malignancies and Beyond. Immunological Reviews, 270, 95-112. [Google Scholar] [CrossRef] [PubMed]
[13] Nooka, A.K., Kaufman, J.L., Hofmeister, C.C., et al. (2019) Daratumumab in Multiple Myeloma. Cancer, 125, 2364-2382. [Google Scholar] [CrossRef] [PubMed]
[14] Lebel, E., Nachmias, B., Pick, M., et al. (2022) Understanding the Bioac-tivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma. Journal of Clinical Medi-cine, 11, 1809. [Google Scholar] [CrossRef] [PubMed]
[15] Akhmetzyanova, I., Mccarron, M.J., Parekh, S., et al. (2020) Dynamic CD138 Surface Expression Regulates Switch between Myeloma Growth and Dissemination. Leukemia, 34, 245-256. [Google Scholar] [CrossRef] [PubMed]
[16] Trowbridge, I.S. and Thomas, M.L. (1994) CD45: An Emerging Role as a Protein Tyrosine Phosphatase Required for Lymphocyte Activation and Development. Annual Review of Im-munology, 12, 85-116. [Google Scholar] [CrossRef] [PubMed]
[17] Pellat-Deceunynck, C. and Bataille, R. (2004) Normal and Malignant Human Plasma Cells: Proliferation, Differentiation, and Expansions in Relation to CD45 Expression. Blood Cells, Molecules, and Diseases, 32, 293-301. [Google Scholar] [CrossRef] [PubMed]
[18] Kumar, S., Rajkumar, S.V., Kimlinger, T., et al. (2005) CD45 Expression by Bone Marrow Plasma Cells in Multiple Myeloma: Clinical and Biological Correlations. Leukemia, 19, 1466-1470. [Google Scholar] [CrossRef] [PubMed]
[19] Gonsalves, W.I., Timm, M.M., Rajkumar, S.V., et al. (2016) The Prognostic Significance of CD45 Expression by Clonal Bone Marrow Plasma Cells in Patients with Newly Diagnosed Multiple Myeloma. Leukemia Research, 44, 32-39. [Google Scholar] [CrossRef] [PubMed]
[20] Pick, M., Vainstein, V., Goldschmidt, N., et al. (2018) Daratu-mumab Resistance Is Frequent in Advanced-Stage Multiple Myeloma Patients Irrespective of CD38 Expression and Is Related to Dismal Prognosis. European Journal of Haematology, 100, 494-501. [Google Scholar] [CrossRef] [PubMed]
[21] Moreau, P., Robillard, N., Avet-Loiseau, H., et al. (2004) Patients with CD45 Negative Multiple Myeloma Receiving High-Dose Therapy Have a Shorter Survival than Those with CD45 Posi-tive Multiple Myeloma. Haematologica, 89, 547-551.
[22] Agematsu, K., Nagumo, H., Oguchi, Y., et al. (1998) Gener-ation of Plasma Cells from Peripheral Blood Memory B Cells: Synergistic Effect of Interleukin-10 and CD27/CD70 In-teraction. Blood, 91, 173-180. [Google Scholar] [CrossRef] 
[23] Guikema, J.E., Hovenga, S., Vellenga, E., et al. (2003) CD27 Is Heterogeneously Expressed in Multiple Myeloma: Low CD27 Expression in Patients with High-Risk Disease. British Journal of Haematology, 121, 36-43. [Google Scholar] [CrossRef] [PubMed]
[24] Chu, B., Bao, L., Wang, Y., et al. (2020) CD27 Antigen Negative Expression Indicates Poor Prognosis in Newly Diagnosed Multiple Myeloma. Clinical Immunology, 213, Arti-cle ID: 108363. [Google Scholar] [CrossRef] [PubMed]
[25] Wang, K., Wei, G. and Liu, D. (2012) CD19: A Biomarker for B Cell Development, Lymphoma Diagnosis and Therapy. Experimental Hematology & Oncology, 1, 36. [Google Scholar] [CrossRef] [PubMed]
[26] Barwick, B.G., Gupta, V.A., Vertino, P.M., et al. (2019) Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. Frontiers in Immunology, 10, 1121. [Google Scholar] [CrossRef] [PubMed]
[27] Gao, M., Kong, Y., Yang, G., et al. (2016) Multiple Myeloma Cancer Stem Cells. Oncotarget, 7, 35466-35477. [Google Scholar] [CrossRef] [PubMed]
[28] Johnsen, H.E., Bøgsted, M., Schmitz, A., et al. (2016) The Myeloma Stem Cell Concept, Revisited: From Phenomenology to Operational Terms. Haematologica, 101, 1451-1459. [Google Scholar] [CrossRef] [PubMed]
[29] Garfall, A.L., Maus, M.V., Hwang, W.T., et al. (2015) Chi-meric Antigen Receptor T Cells against CD19 for Multiple Myeloma. The New England Journal of Medicine, 373, 1040-1047. [Google Scholar] [CrossRef] 
[30] Bahlis, N.J., King, A.M., Kolonias, D., et al. (2007) CD28-Mediated Regulation of Multiple Myeloma Cell Proliferation and Survival. Blood, 109, 5002-5010. [Google Scholar] [CrossRef] [PubMed]
[31] Zhang, P.P., Li, J.J., Hu, Z.L., et al. (2022) Clinical Signifi-cance of CD28 Expression in Newly Diagnosed Multiple Myeloma. Journal of Experimental Hematology, 30, 1785-1790.
[32] Li, L., Li, X., Shang, A., et al. (2022) Prognostic Significance of CD56 Antigen in Newly Diagnosed Multiple Myeloma: A Real-World Retrospective Study. Medicine (Baltimore), 101, e30988. [Google Scholar] [CrossRef] 
[33] Ngo, N.T., Brodie, C., Giles, C., et al. (2009) The Signifi-cance of Tumour Cell Immunophenotype in Myeloma and Its Impact on Clinical Outcome. Journal of Clinical Pathology, 62, 1009-1015. [Google Scholar] [CrossRef] [PubMed]
[34] Koumpis, E., Tassi, I., Malea, T., et al. (2021) CD56 Expression in Multiple Myeloma: Correlation with Poor Prognostic Markers but No Effect on Outcome. Pathology Re-search and Practice, 225, Article ID: 153567. [Google Scholar] [CrossRef] [PubMed]
[35] Dragoș, M.L., Ivanov, I.C., Mențel, M., et al. (2022) Prognostic Value of Association of Copy Number Alterations and Cell-Surface Expression Markers in Newly Diagnosed Multiple Myeloma Patients. International Journal of Molecular Sciences, 23, 7530. [Google Scholar] [CrossRef] [PubMed]
[36] Bataille, R., Pellat-Deceunynck, C., Robillard, N., et al. (2008) CD117 (c-kit) Is Aberrantly Expressed in a Subset of MGUS and Multiple Myeloma with Unexpectedly Good Prognosis. Leu-kemia Research, 32, 379-382. [Google Scholar] [CrossRef] [PubMed]
[37] Zismanov, V., Drucker, L., Attar-Schneider, O., et al. (2012) Tetraspanins Stimulate Protein Synthesis in Myeloma Cell Lines. Journal of Cellular Biochemistry, 113, 2500-2510. [Google Scholar] [CrossRef] [PubMed]
[38] Paiva, B., Gutiérrez, N.C., Chen, X., et al. (2012) Clinical Significance of CD81 Expression by Clonal Plasma Cells in High-Risk Smoldering and Symptomatic Multiple Myeloma Patients. Leukemia, 26, 1862-1869. [Google Scholar] [CrossRef] [PubMed]
[39] Arana, P., Paiva, B., Cedena, M.T., et al. (2018) Prognostic Value of An-tigen Expression in Multiple Myeloma: A PETHEMA/GEM Study on 1265 Patients Enrolled in Four Consecutive Clin-ical Trials. Leukemia, 32, 971-978. [Google Scholar] [CrossRef] [PubMed]
[40] Kristiansen, G., Sammar, M. and Altevogt, P. (2004) Tumour Biological Aspects of CD24, a Mucin-Like Adhesion Molecule. Journal of Molecular Histology, 35, 255-262. [Google Scholar] [CrossRef] 
[41] Gross Even-Zohar, N., Pick, M., Hofstetter, L., et al. (2022) CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival. Journal of Clinical Medicine, 11, 2913. [Google Scholar] [CrossRef] [PubMed]

为你推荐